ArticleJournal of cellular and molecular medicine2026
The Secretome Derived From Serum-Free Media of SHED-MSCs Can Modulate THP-1-Derived Macrophage Cells.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug-induced metabolic remodeling promotes antimicrobial activity in macrophages and extends longevity in vivo.Life science alliance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Although culturing cells in serum-free or low-serum media may lead to reduced cell proliferation, it is crucial to minimise the presence of foreign proteins and other impurities that could compromise the validity of experimental findings on immunomodulation. The study aimed to investigate the immunomodulatory effects of the secretome derived from the serum-free media (SFM) of stem cells obtained from human exfoliated deciduous teeth on THP-1-derived macrophage polarisation and the assessment of inflammatory and oxidative stress mediators. THP-1 cells were polarised into M0 and M1 macrophages, and their differentiation was confirmed using flow cytometry to analyse specific markers of M0 (CD14 and CD68) and M1 (CD80 and CD86). The secretome was collected from SHED-MSCs cultured for 48 h in serum-free DMEM/F12 media. After treating THP-1-derived M0/M1 macrophages with SFM-secretome from SHED-MSCs, cells and supernatants were evaluated for immunosuppressive (anti-inflammatory and antioxidant) and immunostimulatory (pro-inflammatory and pro-oxidant) indicators. Secretome treatment decreased the population of M1 macrophages, along with the expression of pro-inflammatory and pro-oxidative markers, including CD80, CD86, TNF-α, IL-12, NO, MDA and IL-6R. The immunomodulatory effect of the secretome produced by SFM, which may help reduce inflammation, is demonstrated by an increase in M2 macrophages and anti-inflammatory and antioxidant markers, including CD206, TGFβ-2, IL-10, TAC, CAT, SOD and ARG1. The secretome produced by SFM-derived SHED-MSCs may reduce the risk of introducing foreign proteins and other potentially hazardous chemicals and enhance the efficacy of cellular secretions for applications such as immunotherapy or regenerative medicine by modulating the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.